Navigation Links
BLAST in Medical Technology

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...should not be taken to make up for any missed dose. * Numbers indicate the range of percentages in 4 studies among adult patients with Ph+ CML in blast crisis, accelerated phase, and chronic phase. (+) For more detailed study information, please see full Prescribing Information. Disclaimer ...

For Iraq Veterans, Headaches Continue After Traumatic Brain Injury

...Newswire-USNewswire/ -- Many soldiers who experienced mild head trauma or a blast exposure while serving in Iraq or Afghanistan are returning to the United S...aq or Afghanistan in 2008. All had experienced a concussion, head injury or blast exposure while deployed. Nearly 98 percent of the soldiers reported h...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... limited to 5 years. Gleevec is also indicated for patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after fai...n 4 studies among adult patients, with newly diagnosed Ph+ CML, patients in blast crisis, accelerated phase, and in the chronic phase after failure of interf...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

...percent. An additional 5 patients had bone marrow blast reductions to less than 5 percent. The median dur...overy. Three additional patients with bone marrow blast reductions are undergoing second induction cycles ...ized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lympho...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

...ymphoma/leukemia as defined by the Revised European-American Lymphoma (REAL) criteria, acute myeloid leukemia (AML), chronic myeloid leukemia (CML) in blast crisis, or high grade myelodysplastic syndrome (MDS) with >10% bone marrow involvement. Potential risk for TLS was defined as diagnosis of aggressi...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... limited to 5 years. Gleevec is also indicated for patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in the chronic phase (CP) after fai...n 4 studies among adult patients, with newly diagnosed Ph+ CML, patients in blast crisis, accelerated phase and in the chronic phase after failure of interfe...

Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH

... About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

...r types. About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

...ated for the treatment of patients with Ph+ CML in blast crisis (BC), accelerated phase (AP), or in chronic... in 4 studies among adult patients with Ph+ CML in blast crisis, accelerated phase, and chronic phase. Fo... in 4 studies among adult patients with Ph+ CML in blast crisis, accelerated phase, and chronic phase. (+...

Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

... previous therapy with growth factors, immunosuppressive agents or hydroxyurea. In order to participate in the study, patients had to have bone marrow blast counts between 11 and 30 percent. Patients with blast counts below 10 percent were required to have had poor-risk cytogenetics in order to be eligible...

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

... previous therapy with growth factors, immunosuppressive agents or hydroxyurea. In order to participate in the study, patients had to have bone marrow blast counts between 11 and 30 percent. Patients with blast counts below 10 percent were required to have had poor prognosis cytogenetics in order to be eli...

Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

...r types. About Acute Myeloid Leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths ...

Exelixis Presents Clinical Data Supporting the Safety and Initial Clinical Activity of XL228 in Chronic and Acute Leukemia

...patient with an F317L BCR-ABL mutation in lymphoid blast crisis experienced a marked decrease in peripheral blast counts on XL228 (7.2 mg/kg) and hydroxyurea which ...of tumor lysis syndrome in a patient with lymphoid blast crisis receiving concurrent treatment with hydroxy...

Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia

...loxin of 50 mg/m2 or greater on a weekly dose schedule achieved bone marrow blast reductions to less than five percent, and five of those 13 achieved either ...er of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The American Cancer Society estimates that over 1...

Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury

...in injury has also been described as the signature injury of the wars in Iraq and Afghanistan. As many as 400,000 U.S. servicemen have been exposed to blast injuries and could have varying degrees of TBI. Application of HBOT to these veterans could have a significant impact on their return to work, quality...

Gemin X Presents Positive Preclinical Data of GX15-070 in Infant ALL at AACR Meeting

...o the study, GX15-070 demonstrated potent single agent activity against ALL blast cells, and also enhanced chemosensitivity and was synergistic with cytotoxi...l death process of apoptosis. In this study, researchers obtained leukemia blast cells from five infants and one child with primary ALL. The blasts were exp...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...ents was 12.6 months, the median duration of response was 8.8 months, and 1- and 2-year survival rates were 51% and 26%, respectively. Regardless of blast percentage, cytogenetics, or age, responses were observed in all risk groups. Additionally, the survival of the Dacogen treated group compared favorab...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...al hematopoietic blood elements (CRi) and one partial response (PR). Additionally, in the twice-weekly 40 mg/m2 dose cohort, one of three patients had blast reduction of more than 95 percent and that patient achieved a complete remission (CR). Several patients have gone on to receive and tolerate multiple ...

Cytokinetics Reports Additional Clinical Trials Data for Ispinesib

...harmacokinetics of ispinesib on an alternative dosing schedule in patients with relapsed or refractory acute leukemia, chronic myelogenous leukemia in blast crisis, or advanced myelodysplastic syndromes. Data from this trial are expected in 2007. Background on Mitotic Kinesin Inhibitors Since their in...
Other Tags
(Date:8/25/2015)... and BELLEVUE, Wash. , Aug. 25, ... robotic systems, announced today it will unveil its "Guardian ... (UGV), at the National Tactical Officers Association Conference on ... The Guardian S is the first-ever commercially available energetically ... of research and in-field trials and is protected by ...
(Date:8/24/2015)... , Aug. 24, 2015  Based on its recent ... DERMALOG with the 2015 African Biometrics Company of the Year ... achieved substantial commercial success in Africa . ... , where it has implemented one of the largest biometric ... as well as the Central Bank of Nigeria ...
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the world ... be spotlighting its award-winning print and artwork inspection solutions, ScanProof and ArtProof ... 17 at the Olympia London, booth #F33 , Be the first to get a ...
(Date:9/3/2015)... ... , ... Hunters Creek Retrievers is again honored to salute America's ... Puppy. Celebrate Fall 2015 with unlimited Free Hugs and K9 Kisses from a premiere ... Christmas with an extra big smile. , This adorable trained Lab Pup is ...
(Date:9/3/2015)... ... September 03, 2015 , ... A scar is an unavoidable result of incision or ... of the body's ability to heal itself. The appearance of a scar is dependent on ... age, genes, and skin pigmentation. ”Many scars fade to near invisibility on their own over ...
(Date:9/3/2015)... MS (PRWEB) , ... September 03, 2015 , ... ... that their team will be participating at the highly anticipated Mississippi Gulf Babypalooza ... expectant mothers coming from all over, from Gulfport, Biloxi, and beyond. We will ...
(Date:9/3/2015)... Rosa, CA (PRWEB) , ... September 03, 2015 , ... About 220,800 new cases of ... One in seven men will be diagnosed with prostate cancer during their lifetime. While only ... to six of every 10 men by age 65, according to the American Cancer ...
Breaking Medicine News(10 mins):Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 2Health News:Hunters Creek Retrievers Is Honored to Support the Lone Survivor Foundation with a Championship Trained Black Labrador Retriever Puppy 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 2Health News:Noted Santa Rosa Urologist Dr. Michael Lazar Provides Insights on Prostate Cancer Treatments in Recognition of Prostate Cancer Awareness Month 3
Other Contents